Synthetic Biologics Inc (SYN) Downgraded by Laurentian to Speculative Buy
A number of other equities research analysts have also recently commented on SYN. FBR & Co restated a buy rating on shares of Synthetic Biologics in a research report on Friday, August 5th. Zacks Investment Research upgraded Synthetic Biologics from a hold rating to a buy rating and set a $2.00 target price on the stock in a research report on Tuesday, August 9th. BTIG Research started coverage on Synthetic Biologics in a research report on Thursday, August 25th. They set a buy rating and a $5.00 target price on the stock. Griffin Securities set a $5.80 target price on Synthetic Biologics and gave the company a buy rating in a research report on Wednesday, August 31st. Finally, Laurentian Bank of Canada cut Synthetic Biologics from a buy rating to a speculative buy rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Synthetic Biologics presently has a consensus rating of Buy and a consensus price target of C$5.41.
Shares of Synthetic Biologics (NYSEMKT:SYN) traded up 1.2302% during midday trading on Friday, reaching $0.8805. The company’s stock had a trading volume of 470,457 shares. The firm’s market cap is $81.16 million. Synthetic Biologics has a one year low of $0.82 and a one year high of $3.09. The stock’s 50 day moving average price is $1.39 and its 200 day moving average price is $1.70.
Synthetic Biologics (NYSEMKT:SYN) last posted its earnings results on Tuesday, November 1st. The company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.01. Analysts predict that Synthetic Biologics will post ($0.35) earnings per share for the current year.
An institutional investor recently raised its position in Synthetic Biologics stock. UBS Group AG boosted its stake in shares of Synthetic Biologics Inc (NYSEMKT:SYN) by 378.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 288,367 shares of the company’s stock after buying an additional 228,037 shares during the period. UBS Group AG owned about 0.32% of Synthetic Biologics worth $680,000 as of its most recent filing with the SEC.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Stock Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related stocks with our FREE daily email newsletter.